The aim of this review is to provide an up-to-date overview of treatment approaches for systemic lupus erythematosus (SLE), highlighting the multiplicity and heterogeneity of clinical symptoms that underlie therapeutic decisions. Discussion will focus on the spectrum of currently available therapies, their mechanisms and associated side-effects. Finally, recent developments with biologic treatments including rituximab, epratuzumab, tumor necrosis factor (TNF) inhibitors, and belimumab, will be discussed.
Landmark research has shown clearly that oral contraceptives do not increase the rate of flares of systemic lupus erythematosus. This important finding is opposite to what has been thought for years. Now we can reassure women with lupus that if they take birth-control pills, they are not increasing their risk for lupus flares. Note: Birth-control pills or any estrogen medications are still be avoided by women who are at increased risk of blood clotting, such as women with lupus who have phospholipid antibodies (including cardiolipin antibody and lupus anticoagulant).
Blood and urine tests. The antinuclear antibody (ANA) test can show if your immune system is more likely to make the autoantibodies of lupus. Most people with lupus test positive for ANA. But, a positive ANA does not always mean you have lupus. If you test positive for ANA, your doctor will likely order more tests for antibodies that are specific to systemic lupus erythematosus (SLE).
At Benaroya Research Institute at Virginia Mason (BRI), research programs study the cells which regulate lupus to further understand disease pathogenesis - or the development of the disease – translating these findings into therapeutic targets. In addition, clinical trials are ongoing to evaluate novel therapies in this disease. BRI has a Clinical Research Registry people can join to learn about clinical trials that may be appropriate for them.
The GRADE approach was followed in the process (http://www.gradeworkinggroup.org) answering the clinical questions voted most relevant by the panel. The description of the methodology followed to develop these guidelines has already been published.29 All authors listed in this manuscript have participated in planning, drafting, reviewing, final approval and are accountable for all aspects of the manuscript. No ethical approval was required by institutions. We present the final recommendations and their supporting information. Comments from three patients with SLE were also considered.
There is a wide range of diets advertised to help you lose weight quickly or control various chronic diseases, such as lupus. Many people claim to be experts in nutrition yet have limited knowledge and offer no protection to the public. You should be wary of unqualified practitioners who may be offering unproven techniques to diagnose and treat nutritional problems.
For resistant skin disease, other antimalarial drugs, such as chloroquine (Aralen) or quinacrine, are considered and can be used in combination with hydroxychloroquine. Alternative medications for skin disease include dapsone and retinoic acid (Retin-A). Retin-A is often effective for an uncommon wart-like form of lupus skin disease. For more severe skin disease, immunosuppressive medications are considered as described below.
Research indicates that omega 3 fatty acids from fish or fish oils may help manage high triglycerides and heart disease (see references at end of this summary). There have not been any studies, however, that show a reduced disease activity with lupus. Foods rich in omega 3 fatty acids include salmon, sardines, mackerel, bluefish, herring, mullet, tuna, halibut, lake trout, rainbow trout, ground flaxseed, walnuts, pecans, canola oil, walnut oil, and flaxseed oil, and are part of a heart-healthy meal plan.
Combination treatment: Health care providers may combine a few medications to control lupus and prevent tissue damage. Each treatment has risks and benefits. Most immune-suppressing medications may cause side effects and require close monitoring. Side effects of these drugs may include a raised risk of infections as well as nausea, vomiting, hair loss, diarrhea, high blood pressure, and osteoporosis (weak bones). Rheumatologists may lower the dose of a drug or stop a medicine because of side effects or when the disease goes into remission. As a result, it is important to receive careful and frequent health exams and lab tests to track your symptoms and change your treatment as needed.
Prognosis is typically worse for men and children than for women; however, if symptoms are present after age 60, the disease tends to run a more benign course. Early mortality, within 5 years, is due to organ failure or overwhelming infections, both of which can be altered by early diagnosis and treatment. The mortality risk is fivefold when compared to the normal population in the late stages, which can be attributed to cardiovascular disease from accelerated atherosclerosis, the leading cause of death for people with SLE. To reduce the potential for cardiovascular issues, high blood pressure and high cholesterol should be prevented or treated aggressively. Steroids should be used at the lowest dose for the shortest possible period, and other drugs that can reduce symptoms should be used whenever possible.
Corticosteroids also can cause or worsen osteoporosis, a disease in which bones become fragile and more likely to break. If you have osteoporosis, you should eat foods rich in calcium every day to help with bone growth. Examples are dark green, leafy vegetables (spinach, broccoli, collard greens), milk, cheese, and yogurt or calcium supplements that contain Vitamin D.
A complex of genes on chromosome 6 that code for the antigens that determine tissue and blood compatibility. In humans, histocompatibility antigens are called human leukocyte antigens (HLA) because they were originally discovered in large numbers on lymphocytes. There are thousands of combinations of HLA antigens. Class I MHC antigens (HLA-A, HLA-B, and HLA-C) are found on all nucleated cells and platelets. Class II antigens (HLA-DR, HLA-DQ, and HLA-DP) are found on lymphocytes and antigen processing cells and are important in the specific immune response. In tissue and organ transplantation, the extent to which the HLA or “tissue type” of the donor and recipient match is a major determinant of the success of the transplant.
If cyclophosphamide doesn’t work for patients with lupus nephritis, they now have the option of trying another drug, and more options are being tested in clinical trials, says Dr. Caricchio. For example, doctors may use CellCept (mycophenolate mofetil), Imuran (azathioprine), or Restasis (cyclosporine). Prograf (tacrolimus) may also be an effective option for lupus nephritis, according to study data appearing in the January 2016 edition of Autoimmunity Reviews. (5)
Affiliate Disclosure: There are links on this site that can be defined as affiliate links. This means that I may receive a small commission (at no cost to you) if you purchase something when clicking on the links that take you through to a different website. By clicking on the links, you are in no way obligated to buy.
Please Note: The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any diet or exercise program.
Copyright © livehopelupus.org